It has been reported that PPARγ agonist could block classical activation of macrophages and attenuates inflammation in diabetic atherosclerosis, thus may promote a more favourable plaque morphology.43, 44 In addition, atherosclerosis is also affected by lipid profiles and glucose metabolism.45, 46 There was a trend towards a decrease in blood glucose levels in the 20(S)‐Rg3–treated diabetic mice, which might also contribute to its anti‐atherosclerotic effects.47 This evidence concerns the gene PPARG and atherosclerosis.